News
Resources
Blog
Sites
New report shows more than 260 medicines in development to fight neurodegenerative diseases
By Andrew Powaleny | October 12, 2021
With neurodegenerative diseases affecting millions of individuals in the United States, now is an important time to spotlight the increasing impact these diseases have on our country’s aging...
Read More
The important role of antivirals in the fight against COVID-19
By Richard Moscicki, M.D. | October 6, 2021
Throughout the COVID-19 pandemic, public health officials have focused their response into four main areas: 1) rapid and accurate testing: 2) contact tracing systems to monitor outbreaks; 3)...
Read More
Understanding Long COVID-19
By Richard Moscicki, M.D. | September 29, 2021
The Centers for Disease Control and Prevention (CDC) defines long COVID as health problems lasting four or more weeks after first getting infected with the novel coronavirus, impacting as many as ...
Read More
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
By Richard Moscicki, M.D. | September 28, 2021
Last week, the U.S. Food and Drug Administration (FDA) released the Performance Goals Letter for the Biosimilar User Fee Act (BsUFA) III.
Read More
Meeting Tomorrow: Looking ahead to PDUFA VII
By Andrew Powaleny | September 27, 2021
Tomorrow, PhRMA will participate at the U.S. Food and Drug Administration’s (FDA) public meeting on the reauthorization of the Prescription Drug User Fee Act (PDUFA VII).
Read More
PhRMA releases 2021 industry profile
By Gabby Migliara | September 20, 2021
Today, PhRMA released its 2021 Biopharmaceutical Industry Profile, a resource that highlights the latest from the industry on innovation, access and affordability. The Profile has told the story...
Read More
Addressing data challenges to improve health equity
By Emily Donaldson | September 17, 2021
The COVID-19 pandemic has shed light on the ways that systemic racism pervades nearly every facet of life – especially within our health care system. The biopharmaceutical industry is dedicated to...
Read More
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
By Joseph Havey | September 8, 2021
Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. Already, we’ve...
Read More
Patients and innovators lose if the government pursues ‘march-in’
By Megan Van Etten | September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...
Read More
The impact of monoclonal antibodies and COVID-19 recovery
By Andrew Powaleny | September 2, 2021
As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
